AL2846, a novel multi-kinase inhibitor, for previously treated radioiodine-refractory differentiated thyroid cancer: Exploratory clinical results from the phase Ib study | Synapse
AL2846, a novel multi-kinase inhibitor, for previously treated radioiodine-refractory differentiated thyroid cancer: Exploratory clinical results from the phase Ib study
To evaluate the safety and antitumor activity of AL2846 in previously treated radioiodine-refractory differentiated thyroid cancer (RR-DTC).
Phase Ib clinical trial design
Participants were previously treated with other tyrosine kinase inhibitors (TKIs)
Administration of AL2846 at a dosage of 90 mg
AL2846 demonstrated an acceptable safety profile
Promising antitumor activity observed in patients
90 mg dosage exhibited more favorable effects than lower doses
Abstract
AL2846 showed an acceptable safety profile and a promising antitumor activity in previously TKI treated RR-DTC patients, with 90 mg has a more favorable effect.